James Lah, MD
Neurology · Atlanta, GANPI 1952358582
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,900 of the $3,013 with a category attached, or 96.2%. Roche Diagnostics Corporation accounts for 96.2% of it on its own, with 2 other manufacturers making up the rest.
Across 5 payments — averaging $602.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$3K
- Lilly USA, LLC$66
- Eisai Inc.$48
Across 214 payments — averaging $31,965 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Corporation$4.4M
- Eisai Inc.$952K
- AbbVie$859K
- Eli Lilly$466K
- Roche Diagnostics Operations, Inc.$121K
- Genentech, Inc.$37K
- plus $10K from 2 others
What the payments were for
- Speaking & faculty fees$2,90096%
- Food & beverage$1134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 1 | $2,900 |
| Lilly USA, LLC | 3 | $66 |
| Eisai Inc. | 1 | $48 |
How this compares
$3,013 in reported general payments places this provider in the 60th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 42 | $6,560 |
| Memantine Hcl | 158 | $4,312 |
| Galantamine ErGalantamine Hbr | 46 | $3,289 |
| Donepezil Hcl | 274 | $2,650 |
| Memantine Hcl ErMemantine Hcl | 12 | $1,637 |
| Sertraline Hcl | 114 | $1,020 |
| Escitalopram Oxalate | 84 | $731 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $317 |
| Trazodone Hcl | 27 | $317 |
| Duloxetine Hcl | 13 | $304 |
| Quetiapine Fumarate | 39 | $250 |
| Risperidone | 14 | $203 |
| Lorazepam | 14 | $29 |
Paid to pharmacies, not to this prescriber.
Other neurology in Atlanta
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Robert GilbertAtlanta$412K
- Lawrence SeidenAtlanta$272K
- Jacqueline RosenthalAtlanta$241K
- Ben ThrowerAtlanta$203K
- Jaime Hatcher MartinAtlanta$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.